



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 434 570 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)
INID code(s) 73

(51) Int Cl.7: **A61K 9/22**, A61K 9/52,
A61K 31/517, A61P 13/08

(48) Corrigendum issued on:
26.10.2005 Bulletin 2005/43

(86) International application number:
PCT/IB2002/004040

(45) Date of publication and mention
of the grant of the patent:
31.08.2005 Bulletin 2005/35

(87) International publication number:
WO 2003/032956 (24.04.2003 Gazette 2003/17)

(21) Application number: **02775048.8**

(22) Date of filing: **30.09.2002**

(54) **PHARMACEUTICAL FORMULATIONS FOR THE CONTROLLED RELEASE OF
4-AMINO-6,7-DIMETHOXY-2-(5-METHANESULFONAMIDO-1,2,3,4-TETRAHYDROISOQUINOL-
2-YL)-5-(2-PYRIDYL)QUINAZOLINE**

PHARMAZEUTISCHE FORMULIERUNGEN ZUR GESTEUERTEN FREISETZUNG VON
4-AMINO-6,7-DIMETHOXY-2-(5-METHANESULFONAMIDO-1,2,3,4-TETRAHYDROISOCHINOL-2-
YL)-5-(2-PYRIDYL)CHINAZOLIN

FORMULATIONS PHARMACEUTIQUES DESTINEES A LA LIBERATION CONTROLEE DE
4-AMINO-6,7-DIMETHOXY-2-(5-METHANESULFONAMIDO-1,2,3,4-TETRAHYDROISOQUINOL-2-
-YL)-5-(2-PYRIDYL) QUINAZOLINE

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
IE IT LI LU MC NL PT SE SK TR**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **11.10.2001 GB 0124455**

(43) Date of publication of application:
07.07.2004 Bulletin 2004/28

(73) Proprietors:
• **Pfizer Limited**
Sandwich, Kent CT13 9NJ (GB)
Designated Contracting States:
GB
• **PFIZER INC.**
New York, N.Y. 10017 (US)
Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GR IE
IT LU MC NL PT SE SK TR**

(72) Inventors:
• **DAVIS, John, D.,**
Pfizer Global Research and Dev.
Sandwich, Kent CT13 9NJ (GB)
• **HUMPHREY, Michael, J.,**
Pfizer Global Rch. and Dev.
Sandwich, Kent CT13 9NJ (GB)
• **MACRAE, Ross, J.,**
Pfizer Global Research and Dev.
Sandwich, Kent CT13 9NJ (GB)
• **SMITH, Janet, S.,**
Pfizer Global Research and Dev.
Sandwich, Kent CT13 9NJ (GB)

(74) Representative: **Bridle, Andrew Barry**
Pfizer Limited
UK Patent Department
Ramsgate Road
Sandwich, Kent CT13 9NJ (GB)

(56) References cited:
EP-A- 0 466 986 **EP-A- 1 123 705**
WO-A-01/64672 **WO-A-98/30560**
FR-A- 2 752 737

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 434 570 B8